Cellular immunotherapy in multiple myeloma : lessons from preclinical models

[en] The majority of multiple myeloma patients relapse with the current treatment strategies, raising the need for alternative therapeutic approaches. Cellular immunotherapy is a rapidly evolving field and currently being translated into clinical trials with encouraging results in several cancer types, including multiple myeloma. Murine multiple myeloma models are of critical importance for the development and refinement of cellular immunotherapy. In this review,we summarize the immune cell changes that occur inmultiplemyelomapatients and we discuss the cell-based immunotherapies that have been tested in multiple myeloma, with a focus on murine models.

Disciplines :

Hematology

Author, co-author :

Binsfeld, Marilène ; Université de Liège - ULiège > GIGA-R : Hématologie

Fostier, K.

Muller, Joséphine ; Université de Liège - ULiège > GIGA-R : Hématologie

Baron, Frédéric ; Université de Liège - ULiège > GIGA-R : Hématologie

Schots, R.

Beguin, Yves ; Université de Liège - ULiège > GIGA-R : Hématologie

Heusschen, Roy ; Université de Liège - ULiège > GIGA-R : Hématologie

CAERS, Jo ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Language :

English

Title :

Cellular immunotherapy in multiple myeloma : lessons from preclinical models

Publication date :

2014

Journal title :

Biochimica et Biophysica Acta - Reviews on Cancer

ISSN :

0304-419X

Publisher :

Elsevier Science

Volume :

1846

Pages :

392-404

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 08 October 2014

Statistics

Number of views

198 (11 by ULiège)

Number of downloads

1615 (7 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Caers J., Vande broek I., De Raeve H., Michaux L., Trullemans F., Schots R., et al. Multiple myeloma-an update on diagnosis and treatment. Eur. J. Haematol. 2008, 81(5):329-343.
Potter M., Boyce C.R. Induction of plasma-cell neoplasms in strain BALB/c mice with mineral oil and mineral oil adjuvants. Nature 1962, 193:1086-1087.
Radl J., Croese J.W., Zurcher C., Van den Enden-Vieveen M.H., de Leeuw A.M. Animal model of human disease. Multiple myeloma. Am. J. Pathol. 1988, 132(3):593-597.
Garrett I.R., Dallas S., Radl J., Mundy G.R. A murine model of human myeloma bone disease. Bone 1997, 20(6):515-520.
Bruns I., Cadeddu R.P., Brueckmann I., Frobel J., Geyh S., Bust S., et al. Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells. Blood 2012, 120(13):2620-2630.
Roeven M.W., Hobo W., Schaap N., Dolstra H. Immunotherapeutic approaches to treat multiple myeloma. Hum. Vaccin. Immunother. 2013, 10(4).
Cook G., Campbell J.D. Immune regulation in multiple myeloma: the host-tumour conflict. Blood Rev. 1999, 13(3):151-162.
Harrison S.J., Cook G. Immunotherapy in multiple myeloma-possibility or probability?. Br. J. Haematol. 2005, 130(3):344-362.
Quach H., Ritchie D., Stewart A.K., Neeson P., Harrison S., Smyth M.J., et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010, 24(1):22-32.
Dasanu C.A. Immune alterations in untreated and treated multiple myeloma. J. Oncol. Pharm. Pract. 2012, 18(2):257-263.
Feyler S., Selby P.J., Cook G. Regulating the regulators in cancer-immunosuppression in multiple myeloma (MM). Blood Rev. 2013, 27(3):155-164.
Rossi M., Botta C., Correale P., Tassone P., Tagliaferri P. Immunologic microenvironment and personalized treatment in multiple myeloma. Expert. Opin. Biol. Ther. 2013, 13(Suppl. 1):S83-S93.
Mills K.H., Cawley J.C. Abnormal monoclonal antibody-defined helper/suppressor T-cell subpopulations in multiple myeloma: relationship to treatment and clinical stage. Br. J. Haematol. 1983, 53(2):271-275.
Serra H.M., Mant M.J., Ruether B.A., Ledbetter J.A., Pilarski L.M. Selective loss of CD4+ CD45R+ T cells in peripheral blood of multiple myeloma patients. J. Clin. Immunol. 1988, 8(4):259-265.
Hicks M.J., Durie B.G., Slymen D.J. Low circulating T-helper cells in relapsing multiple myeloma. J. Clin. Lab. Anal. 1989, 3(4):202-208.
San Miguel J.F., Gonzalez M., Gascon A., Moro M.J., Hernandez J.M., Ortega F., et al. Lymphoid subsets and prognostic factors in multiple myeloma. Cooperative group for the study of monoclonal gammopathies. Br. J. Haematol. 1992, 80(3):305-309.
Ogawara H., Handa H., Yamazaki T., Toda T., Yoshida K., Nishimoto N., et al. High Th1/Th2 ratio in patients with multiple myeloma. Leuk. Res. 2005, 29(2):135-140.
Schutt P., Brandhorst D., Stellberg W., Poser M., Ebeling P., Muller S., et al. Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. Leuk. Lymphoma 2006, 47(8):1570-1582.
Maecker B., Anderson K.S., von Bergwelt-Baildon M.S., Weller E., Vonderheide R.H., Richardson P.G., et al. Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma. Br. J. Haematol. 2003, 121(6):842-848.
Murakami H., Ogawara H., Hiroshi H. Th1/Th2 cells in patients with multiple myeloma. Hematology 2004, 9(1):41-45.
Fietta P., Delsante G. The effector T helper cell triade. Riv. Biol. 2009, 102(1):61-74.
Sharma A., Khan R., Joshi S., Kumar L., Sharma M. Dysregulation in T helper 1/T helper 2 cytokine ratios in patients with multiple myeloma. Leuk. Lymphoma 2010, 51(5):920-927.
Hong S., Qian J., Yang J., Li H., Kwak L.W., Yi Q. Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth. Cancer Res. 2008, 68(20):8456-8464.
Gorgun G., Calabrese E., Soydan E., Hideshima T., Perrone G., Bandi M., et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 2010, 116(17):3227-3237.
Prabhala R.H., Pelluru D., Fulciniti M., Prabhala H.K., Nanjappa P., Song W., et al. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 2010, 115(26):5385-5392.
Dhodapkar K.M., Barbuto S., Matthews P., Kukreja A., Mazumder A., Vesole D., et al. Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood 2008, 112(7):2878-2885.
Shen C.J., Yuan Z.H., Liu Y.X., Hu G.Y. Increased numbers of T helper 17 cells and the correlation with clinicopathological characteristics in multiple myeloma. J. Int. Med. Res. 2012, 40(2):556-564.
Campbell J.D., Cook G., Robertson S.E., Fraser A., Boyd K.S., Gracie J.A., et al. Suppression of IL-2-induced T cell proliferation and phosphorylation of STAT3 and STAT5 by tumor-derived TGF beta is reversed by IL-15. J. Immunol. 2001, 167(1):553-561.
Atanackovic D., Luetkens T., Kroger N. Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. Leukemia 2014, 28(5):993-1000.
Rosenblatt J., Glotzbecker B., Mills H., Vasir B., Tzachanis D., Levine J.D., et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J. Immunother. 2011, 34(5):409-418.
Benson D.M., Bakan C.E., Mishra A., Hofmeister C.C., Efebera Y., Becknell B., et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010, 116(13):2286-2294.
Tamura H., Ishibashi M., Yamashita T., Tanosaki S., Okuyama N., Kondo A., et al. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia 2013, 27(2):464-472.
Moss P., Gillespie G., Frodsham P., Bell J., Reyburn H. Clonal populations of CD4+ and CD8+ T cells in patients with multiple myeloma and paraproteinemia. Blood 1996, 87(8):3297-3306.
Mariani S., Coscia M., Even J., Peola S., Foglietta M., Boccadoro M., et al. Severe and long-lasting disruption of T-cell receptor diversity in human myeloma after high-dose chemotherapy and autologous peripheral blood progenitor cell infusion. Br. J. Haematol. 2001, 113(4):1051-1059.
Sze D.M., Giesajtis G., Brown R.D., Raitakari M., Gibson J., Ho J., et al. Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8(+)CD57(+)CD28(-) compartment. Blood 2001, 98(9):2817-2827.
Yi Q., Osterborg A. Idiotype-specific T cells in multiple myeloma: targets for an immunotherapeutic intervention?. Med. Oncol. 1996, 13(1):1-7.
Bogen B. Peripheral T, cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur. J. Immunol. 1996, 26(11):2671-2679.
Pilarski L.M., Andrews E.J., Mant M.J., Ruether B.A. Humoral immune deficiency in multiple myeloma patients due to compromised B-cell function. J. Clin. Immunol. 1986, 6(6):491-501.
Rawstron A.C., Davies F.E., Owen R.G., English A., Pratt G., Child J.A., et al. B-lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B-cell progenitors and plasma cell precursors. Br. J. Haematol. 1998, 100(1):176-183.
Brown R.D., Pope B., Murray A., Esdale W., Sze D.M., Gibson J., et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood 2001, 98(10):2992-2998.
Urashima M., Ogata A., Chauhan D., Hatziyanni M., Vidriales M.B., Dedera D.A., et al. Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells. Blood 1996, 87(5):1928-1938.
Carbone E., Neri P., Mesuraca M., Fulciniti M.T., Otsuki T., Pende D., et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 2005, 105(1):251-258.
Gonzalez M., San Miguel J.F., Gascon A., Moro M.J., Hernandez J.M., Ortega F., et al. Increased expression of natural-killer-associated and activation antigens in multiple myeloma. Am. J. Hematol. 1992, 39(2):84-89.
Fauriat C., Mallet F., Olive D., Costello R.T. Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma. Leukemia 2006, 20(4):732-733.
Dhodapkar M.V., Geller M.D., Chang D.H., Shimizu K., Fujii S., Dhodapkar K.M., et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J. Exp. Med. 2003, 197(12):1667-1676.
Chang D.H., Deng H., Matthews P., Krasovsky J., Ragupathi G., Spisek R., et al. Inflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer. Blood 2008, 112(4):1308-1316.
Ratta M., Fagnoni F., Curti A., Vescovini R., Sansoni P., Oliviero B., et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 2002, 100(1):230-237.
Brown R., Murray A., Pope B., Sze D.M., Gibson J., Ho P.J., et al. Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma. Br. J. Haematol. 2004, 125(6):743-748.
Brimnes M.K., Vangsted A.J., Knudsen L.M., Gimsing P., Gang A.O., Johnsen H.E., et al. Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR(-)/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand. J. Immunol. 2010, 72(6):540-547.
Giannopoulos K., Kaminska W., Hus I., Dmoszynska A. The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma. Br. J. Cancer 2012, 106(3):546-552.
Nair J.R., Carlson L.M., Koorella C., Rozanski C.H., Byrne G.E., Bergsagel P.L., et al. CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment. J. Immunol. 2011, 187(3):1243-1253.
Brimnes M.K., Svane I.M., Johnsen H.E. Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma. Clin. Exp. Immunol. 2006, 144(1):76-84.
Yang D.H., Park J.S., Jin C.J., Kang H.K., Nam J.H., Rhee J.H., et al. The dysfunction and abnormal signaling pathway of dendritic cells loaded by tumor antigen can be overcome by neutralizing VEGF in multiple myeloma. Leuk. Res. 2009, 33(5):665-670.
Wang S., Yang J., Qian J., Wezeman M., Kwak L.W., Yi Q. Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood 2006, 107(6):2432-2439.
Wang S., Hong S., Yang J., Qian J., Zhang X., Shpall E., et al. Optimizing immunotherapy in multiple myeloma: restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells. Blood 2006, 108(13):4071-4077.
Joshua D.E., Brown R.D., Ho P.J., Gibson J. Regulatory T cells and multiple myeloma. Clin. Lymphoma Myeloma 2008, 8(5):283-286.
Prabhala R.H., Neri P., Bae J.E., Tassone P., Shammas M.A., Allam C.K., et al. Dysfunctional T regulatory cells in multiple myeloma. Blood 2006, 107(1):301-304.
Beyer M., Kochanek M., Giese T., Endl E., Weihrauch M.R., Knolle P.A., et al. In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood 2006, 107(10):3940-3949.
Feyler S., von Lilienfeld-Toal M., Jarmin S., Marles L., Rawstron A., Ashcroft A.J., et al. CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-)alphabetaTCR(+) double negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br. J. Haematol. 2009, 144(5):686-695.
Muthu Raja K.R., Rihova L., Zahradova L., Klincova M., Penka M., Hajek R. Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. PLoS One 2012, 7(10):e47077.
Feyler S., Scott G.B., Parrish C., Jarmin S., Evans P., Short M., et al. Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent. PLoS One 2012, 7(5):e35981.
Atanackovic D., Cao Y., Luetkens T., Panse J., Faltz C., Arfsten J., et al. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation. Haematologica 2008, 93(3):423-430.
Ostrand-Rosenberg S., Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 2009, 182(8):4499-4506.
Gorgun G.T., Whitehill G., Anderson J.L., Hideshima T., Maguire C., Laubach J., et al. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood 2013, 121(15):2975-2987.
Ramachandran I.R., Martner A., Pisklakova A., Condamine T., Chase T., Vogl T., et al. Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow. J. Immunol. 2013, 190(7):3815-3823.
Van Valckenborgh E., Schouppe E., Movahedi K., De Bruyne E., Menu E., De Baetselier P., et al. Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow. Leukemia 2012, 26(11):2424-2428.
Hoechst B., Ormandy L.A., Ballmaier M., Lehner F., Kruger C., Manns M.P., et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 2008, 135(1):234-243.
Tricot G., Vesole D.H., Jagannath S., Hilton J., Munshi N., Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood 1996, 87(3):1196-1198.
Crawley C., Lalancette M., Szydlo R., Gilleece M., Peggs K., Mackinnon S., et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood 2005, 105(11):4532-4539.
Krishnan A., Pasquini M.C., Logan B., Stadtmauer E.A., Vesole D.H., Alyea E., et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol. 2011, 12(13):1195-1203.
El-Cheikh J., Crocchiolo R., Furst S., Stoppa A.M., Ladaique P., Faucher C., et al. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma. Am. J. Hematol. 2013, 88(5):370-374.
Garban F., Attal M., Michallet M., Hulin C., Bourhis J.H., Yakoub-Agha I., et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006, 107(9):3474-3480.
Bruno B., Rotta M., Patriarca F., Mordini N., Allione B., Carnevale-Schianca F., et al. A comparison of allografting with autografting for newly diagnosed myeloma. N. Engl. J. Med. 2007, 356(11):1110-1120.
Rosinol L., Perez-Simon J.A., Sureda A., de la Rubia J., de Arriba F., Lahuerta J.J., et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008, 112(9):3591-3593.
Bjorkstrand B., Iacobelli S., Hegenbart U., Gruber A., Greinix H., Volin L., et al. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J. Clin. Oncol. 2011, 29(22):3016-3022.
Wirk B., Byrne M., Dai Y., Moreb J.S. Outcomes of salvage autologous versus allogeneic hematopoietic cell transplantation for relapsed multiple myeloma after initial autologous hematopoietic cell transplantation. J. Clin. Med. Res. 2013, 5(3):174-184.
Gahrton G., Iacobelli S., Bjorkstrand B., Hegenbart U., Gruber A., Greinix H., et al. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood 2013, 121(25):5055-5063.
Freytes C.O., Vesole D.H., Lerademacher J., Zhong X., Gale R.P., Kyle R.A., et al. Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantation. Bone Marrow Transplant. 2014, 49(3):416-421.
Kneppers E., van der Holt B., Kersten M.J., Zweegman S., Meijer E., Huls G., et al. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. Blood 2011, 118(9):2413-2419.
Michallet M., Sobh M., El-Cheikh J., Morisset S., Sirvent A., Reman O., et al. Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients. Exp. Hematol. 2013, 41(12):1008-1015.
Zeis M., Steinmann J., Petrela E., Hartung G., Schmitz N., Uharek L. Transfer of idiotypic protein primed allogeneic marrow grafts elicits potent graft-versus-myeloma effects in mice. Bone Marrow Transplant. 2001, 27(3):279-285.
van der Voort R., Volman T.J., Verweij V., Linssen P.C., Maas F., Hebeda K.M., et al. Homing characteristics of donor T cells after experimental allogeneic bone marrow transplantation and posttransplantation therapy for multiple myeloma. Biol. Blood Marrow Transplant. 2013, 19(3):378-386.
Rozemuller H., van der Spek E., Bogers-Boer L.H., Zwart M.C., Verweij V., Emmelot M., et al. A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect. Haematologica 2008, 93(7):1049-1057.
Freeman L.M., Lam A., Petcu E., Smith R., Salajegheh A., Diamond P., et al. Myeloma-induced alloreactive T cells arising in myeloma-infiltrated bones include double-positive CD8+CD4+ T cells: evidence from myeloma-bearing mouse model. J. Immunol. 2011, 187(8):3987-3996.
Guichelaar T., Emmelot M.E., Rozemuller H., Martini B., Groen R.W., Storm G., et al. Human regulatory T cells do not suppress the antitumor immunity in the bone marrow: a role for bone marrow stromal cells in neutralizing regulatory T cells. Clin. Cancer Res. 2013, 19(6):1467-1475.
Hannon M., Lechanteur C., Lucas S., Somja J., Seidel L., Belle L., et al. Infusion of clinical-grade enriched regulatory T cells delays experimental xenogeneic graft-versus-host disease. Transfusion 2014, 54(2):353-363.
Sharabi A., Ghera N.H. Breaking tolerance in a mouse model of multiple myeloma by chemoimmunotherapy. Adv. Cancer Res. 2010, 107:1-37.
Barber A., Meehan K.R., Sentman C.L. Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells. Gene Ther. 2011, 18(5):509-516.
Lauritzsen G.F., Weiss S., Dembic Z., Bogen B. Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors. Proc. Natl. Acad. Sci. U. S. A. 1994, 91(12):5700-5704.
Huang H., Li F., Gordon J.R., Xiang J. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression. Cancer Res. 2002, 62(7):2043-2051.
Huang H., Liu Y., Xiang J. Synergistic effect of adoptive T-cell therapy and intratumoral interferon gamma-inducible protein-10 transgene expression in treatment of established tumors. Cell. Immunol. 2002, 217(1-2):12-22.
Qi Y., Moyana T., Chen Y., Xiang J. Characterization of anti-tumor immunity derived from the inoculation of myeloma cells secreting the fusion protein RM4/IFN-tau. Hum. Antibodies Hybridomas 1996, 7(1):21-26.
Xiang J., Moyana T. Cytotoxic CD4+ T cells associated with the expression of major histocompatibility complex class II antigen of mouse myeloma cells secreting interferon-gamma are cytolytic in vitro and tumoricidal in vivo. Cancer Gene Ther. 1998, 5(5):313-320.
Dou J., Wu Y., Wang J., Zhao F., Chu L., Liu C., et al. Eliciting protective immune responses against murine myeloma challenge in lymphopenia mice through adoptive transfer of tumor antigen-specific lymphocytes and immunization of tumor vaccine secreting mIL-21. Cancer Gene Ther. 2010, 17(10):675-683.
Caligiuri M.A. Human natural killer cells. Blood 2008, 112(3):461-469.
Alici E., Konstantinidis K.V., Sutlu T., Aints A., Gahrton G., Ljunggren H.-G., et al. Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model. Exp. Hematol. 2007, 35(12):1839-1846.
Shi J., Tricot G., Szmania S., Rosen N., Garg T.K., Malaviarachchi P.A., et al. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br. J. Haematol. 2008, 143(5):641-653.
Garg T.K., Szmania S.M., Khan J.A., Hoering A., Malbrough P.A., Moreno-Bost A., et al. Highly activated and expanded natural killer cells for multiple myeloma immunotherapy. Haematologica 2012, 97(9):1348-1356.
Xing D., Ramsay A.G., Gribben J.G., Decker W.K., Burks J.K., Munsell M., et al. Cord blood natural killer cells exhibit impaired lytic immunological synapse formation that is reversed with IL-2 exvivo expansion. J. Immunother. 2010, 33(7):684-696.
Shah N., Martin-Antonio B., Yang H., Ku S., Lee D.A., Cooper L.J.N., et al. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS ONE 2013, 8(10):e76781.
Romagné F., André P., Spee P., Zahn S., Anfossi N., Gauthier L., et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 2009, 114(13):2667-2677.
Benson D.M., Bakan C.E., Zhang S., Collins S.M., Liang J., Srivastava S., et al. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood 2011, 118(24):6387-6391.
Benson D.M., Hofmeister C.C., Padmanabhan S., Suvannasankha A., Jagannath S., Abonour R., et al. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 2012, 120(22):4324-4333.
Korde N., Carlsten M., Lee M.J., Minter A., Tan E., Kwok M., et al. A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Haematologica 2014, 99(6):e81-e83.
Maus M.V., June C.H. Zoom zoom: racing CARs for multiple myeloma. Clin. Cancer Res. 2013, 19(8):1917-1919.
Kalos M., June Carl H. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 2013, 39(1):49-60.
Chu J., Deng Y., Benson D.M., He S., Hughes T., Zhang J., et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 2013, 28(4):917-927.
Hsi E.D., Steinle R., Balasa B., Szmania S., Draksharapu A., Shum B.P., et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin. Cancer Res. 2008, 14(9):2775-2784.
Benson D.M., Byrd J.C. CS1-directed monoclonal antibody therapy for multiple myeloma. J. Clin. Oncol. 2012, 30(16):2013-2015.
Jiang H., Zhang W., Shang P., Zhang H., Fu W., Ye F., et al. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Mol. Oncol. 2014, 8(2):297-310.
Chu J., He S., Deng Y., Zhang J., Peng Y., Hughes T., et al. Genetic modification of T cells redirected towards CS1 enhances eradication of myeloma cells. Clin. Cancer Res. 2014, 20(15):3989-4000.
Mihara K., Bhattacharyya J., Kitanaka A., Yanagihara K., Kubo T., Takei Y., et al. T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells. Leukemia 2012, 26(2):365-367.
CD56 targeted chimeric antigen receptors for immunotherapy of multiple myeloma. Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research 2012, (Chicago, IL). R. Benjamin, M. Condomines, G. Gunset, M. Sadelain (Eds.).
Novak A.J., Darce J.R., Arendt B.K., Harder B., Henderson K., Kindsvogel W., et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 2004, 103(2):689-694.
Carpenter R.O., Evbuomwan M.O., Pittaluga S., Rose J.J., Raffeld M., Yang S., et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin. Cancer Res. 2013, 19(8):2048-2060.
Peinert S., Prince H.M., Guru P.M., Kershaw M.H., Smyth M.J., Trapani J.A., et al. Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen. Gene Ther. 2010, 17(5):678-686.
Casucci M., Nicolis di Robilant B., Falcone L., Camisa B., Norelli M., Genovese P., et al. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood 2013, 122(20):3461-3472.
Garfall A.L., Fraietta J.A., Maus M.V. Immunotherapy with chimeric antigen receptors for multiple myeloma. Discov. Med. 2014, 17(91):37-46.
Nguyen-Pham T.N., Lee Y.K., Kim H.J., Lee J.J. Immunotherapy using dendritic cells against multiple myeloma: how to improve?. Clin. Dev. Immunol. 2012, 2012:397648.
Bogen B. A mouse model for immunotherapy of myeloma. Hematol. J. 2002, 3(5):224-229.
Corthay A., Lundin K.U., Munthe L.A., Froyland M., Gedde-Dahl T., Dembic Z., et al. Immunotherapy in multiple myeloma: Id-specific strategies suggested by studies in animal models. Cancer Immunol. Immunother. 2004, 53(9):759-769.
Lynch R.G., Graff R.J., Sirisinha S., Simms E.S., Eisen H.N. Myeloma proteins as tumor-specific transplantation antigens. Proc. Natl. Acad. Sci. U. S. A. 1972, 69(6):1540-1544.
Bogen B., Malissen B., Haas W. Idiotope-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules. Eur. J. Immunol. 1986, 16(11):1373-1378.
Bogen B., Lambris J.D. Minimum length of an idiotypic peptide and a model for its binding to a major histocompatibility complex class II molecule. EMBO J. 1989, 8(7):1947-1952.
Bogen B., Gleditsch L., Weiss S., Dembic Z. Weak positive selection of transgenic T cell receptor-bearing thymocytes: importance of major histocompatibility complex class II, T cell receptor and CD4 surface molecule densities. Eur. J. Immunol. 1992, 22(3):703-709.
Corthay A., Lundin K.U., Lorvik K.B., Hofgaard P.O., Bogen B. Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells. Cancer Res. 2009, 69(14):5901-5907.
Corthay A., Skovseth D.K., Lundin K.U., Rosjo E., Omholt H., Hofgaard P.O., et al. Primary antitumor immune response mediated by CD4+ T cells. Immunity 2005, 22(3):371-383.
Lauritzsen G.F., Hofgaard P.O., Schenck K., Bogen B. Clonal deletion of thymocytes as a tumor escape mechanism. Int. J. Cancer 1998, 78(2):216-222.
Zeis M., Frenzke H., Schmitz N., Uharek L., Steinmann J. Idiotype protein-pulsed dendritic cells produce strong anti-myeloma effects after syngeneic stem cell transplantation in mice. Bone Marrow Transplant. 2002, 29(3):213-221.
Fredriksen A.B., Sandlie I., Bogen B. Targeted DNA vaccines for enhanced induction of idiotype-specific B and T cells. Front. Oncol. 2012, 2:154.
Fredriksen A.B., Sandlie I., Bogen B. DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells. Mol. Ther. 2006, 13(4):776-785.
Froyland M., Ruffini P.A., Thompson K.M., Gedde-Dahl T., Fredriksen A.B., Bogen B. Targeted idiotype-fusion DNA vaccines for human multiple myeloma: preclinical testing. Eur. J. Haematol. 2011, 86(5):385-395.
Schjetne K.W., Fredriksen A.B., Bogen B. Delivery of antigen to CD40 induces protective immune responses against tumors. J. Immunol. 2007, 178(7):4169-4176.
Fredriksen A.B., Bogen B. Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences. Blood 2007, 110(6):1797-1805.
Qian J., Zheng Y., Zheng C., Wang L., Qin H., Hong S., et al. Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma. Blood 2012, 119(1):161-169.
Hallett W.H., Jing W., Drobyski W.R., Johnson B.D. Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. Biol. Blood Marrow Transplant. 2011, 17(8):1133-1145.
Cohen S., Haimovich J., Hollander N. Dendritic cell-based therapeutic vaccination against myeloma: vaccine formulation determines efficacy against light chain myeloma. J. Immunol. 2009, 182(3):1667-1673.
Hong S., Li H., Qian J., Yang J., Lu Y., Yi Q. Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity. Clin. Exp. Immunol. 2012, 170(2):167-177.
Liu Y., Zhang W., Chan T., Saxena A., Xiang J. Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity. Leuk. Res. 2002, 26(8):757-763.
Hao S., Bi X., Xu S., Wei Y., Wu X., Guo X., et al. Enhanced antitumor immunity derived from a novel vaccine of fusion hybrid between dendritic and engineered myeloma cells. Exp. Oncol. 2004, 26(4):300-306.
Wang S., Hong S., Wezeman M., Qian J., Yang J., Yi Q. Dendritic cell vaccine but not idiotype-KLH protein vaccine primes therapeutic tumor-specific immunity against multiple myeloma. Front. Biosci. 2007, 12:3566-3575.
Curti A., Tosi P., Comoli P., Terragna C., Ferri E., Cellini C., et al. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. Br. J. Haematol. 2007, 139(3):415-424.
Zahradova L., Mollova K., Ocadlikova D., Kovarova L., Adam Z., Krejci M., et al. Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma-phase II study results. Neoplasma 2012, 59(4):440-449.
Rosenblatt J., Avivi I., Vasir B., Uhl L., Munshi N.C., Katz T., et al. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin. Cancer Res. 2013, 19(13):3640-3648.
Hofgaard P.O., Jodal H.C., Bommert K., Huard B., Caers J., Carlsen H., et al. A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease. PLoS One 2012, 7(12):e51892.
McCarthy H., Ottensmeier C.H., Hamblin T.J., Stevenson F.K. Anti-idiotype vaccines. Br. J. Haematol. 2003, 123(5):770-781.
Houot R., Levy R. Vaccines for lymphomas: idiotype vaccines and beyond. Blood Rev. 2009, 23(3):137-142.
Reichardt V.L., Okada C.Y., Liso A., Benike C.J., Stockerl-Goldstein K.E., Engleman E.G., et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-a feasibility study. Blood 1999, 93(7):2411-2419.
Morito N., Yoh K., Maeda A., Nakano T., Fujita A., Kusakabe M., et al. A novel transgenic mouse model of the human multiple myeloma chromosomal translocation t(14;16)(q32;q23). Cancer Res. 2011, 71(2):339-348.
Carrasco D.R., Sukhdeo K., Protopopova M., Sinha R., Enos M., Carrasco D.E., et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell 2007, 11(4):349-360.
Chesi M., Robbiani D.F., Sebag M., Chng W.J., Affer M., Tiedemann R., et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 2008, 13(2):167-180.
Vera J., Savoldo B., Vigouroux S., Biagi E., Pule M., Rossig C., et al. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood 2006, 108(12):3890-3897.